Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.46 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 13/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MC4R | P32245 | 4/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.39 |
| ▸ | F9 | P00740 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
| ▸ | F12 | P00748 | 1/20 | 0.37 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.37 |
| ▸ | F7 | P08709 | 1/20 | 0.37 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5651368 | 0.91 | P2RX7 (0.40) | SCN10ASCN2AF2P2RX7 | |
| SCHEMBL5649545 | 0.88 | F2 (0.48) | SCN10ASCN2AF2CYP3A4PRSS1 | |
| SCHEMBL5647344 | 0.87 | F2 (0.45) | SCN10ASCN2AF2CYP3A4PRSS1 | |
| SCHEMBL5647216 | 0.85 | F2 (0.42) | SCN10ASCN2AF2PRSS1PRSS2 | |
| SCHEMBL5651281 | 0.84 | P2RX7 (0.42) | F2CYP3A4PRSS1F9F10 | |
| SCHEMBL5647797 | 0.83 | F2 (0.45) | F2CYP3A4PRSS1P2RX7 | |
| SCHEMBL5647173 | 0.83 | KLKB1 (0.43) | SCN10ASCN2AF2PRSS1 | |
| SCHEMBL5968590 | 0.82 | SCN10A (0.42) | SCN10ASCN2AF2P2RX7 | |
| Acetic Acid SCHEMBL5648247 | 0.81 | F2 (0.45) | F2CYP3A4PRSS1P2RX7 | |
| SCHEMBL5649670 | 0.80 | P2RX7 (0.48) | F2CYP3A4PRSS1P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070161643-A1 | Pyridin-2-one compounds useful as inhibitors of thrombin | ASTRAZENECA AB (SE) | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161643-A1 | Pyridin-2-one compounds useful as inhibitors of thrombin | PLG, F2, PLAT | SCN10A 4016/4885SCN2A 4150/4885F2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.